RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial – JAMA Oncology

Commentary on Twitter

Apatinib offered significant clinical benefits in terms of both prolonged progression-free survival and overall survival in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. https://t.co/I14AyxKZNS

— JAMA Oncology (@JAMAOnc) December 16, 2021